BACKGROUND: The flank is commonly used for primary xenografts in mice, but it is rare for these tumors to metastasize. Tail vein injection creates a pattern of metastases, but is artificial. We hypothesized that the liver is a convenient alternative xenograft site and that metastases would gradually proceed spontaneously. MATERIALS AND METHODS: Using 15 NOD.CB17-Prkdc(scid)/NcrCrl (NOD/SCID) mice, 10,000 A549 cells were xenografted into the liver while a second group of five mice were xenografted in the flank with 100,000 A549 cells as a control. Mice were euthanized and grossly dissected at 7 wk. A third group of seven mice received liver xenografts with A549 and a mouse each week was euthanized for 7 wk and evaluated. The liver, lung, and spleen were examined histologically. RESULTS: At 7 wk, 15/15 liver xenografted mice had gross primary tumor in the liver. Histologic review confirmed multiple microscopic foci of metastatic disease in all mice (15/15) throughout the lungs, mediastinal nodes, and spleen. The control group had primary tumor in the flank (4/5), but none had histologic evidence of metastases. Serially euthanized liver xenografted mice revealed evidence of a gradual spontaneous metastatic model system with the first histologic findings of micrometastases appearing in the lungs by wk 5, which became wide spread by wk 7. Splenic and mediastinal lymph node metastases developed in wk 6 and 7. CONCLUSIONS: Liver xenografting of A549 cells into NOD/SCID mice is a reliable way of developing widespread micrometastases. This model allows the study of a gradually developing solid tumor with subsequent metastatic spread.
BACKGROUND: The flank is commonly used for primary xenografts in mice, but it is rare for these tumors to metastasize. Tail vein injection creates a pattern of metastases, but is artificial. We hypothesized that the liver is a convenient alternative xenograft site and that metastases would gradually proceed spontaneously. MATERIALS AND METHODS: Using 15 NOD.CB17-Prkdc(scid)/NcrCrl (NOD/SCID) mice, 10,000 A549 cells were xenografted into the liver while a second group of five mice were xenografted in the flank with 100,000 A549 cells as a control. Mice were euthanized and grossly dissected at 7 wk. A third group of seven mice received liver xenografts with A549 and a mouse each week was euthanized for 7 wk and evaluated. The liver, lung, and spleen were examined histologically. RESULTS: At 7 wk, 15/15 liver xenografted mice had gross primary tumor in the liver. Histologic review confirmed multiple microscopic foci of metastatic disease in all mice (15/15) throughout the lungs, mediastinal nodes, and spleen. The control group had primary tumor in the flank (4/5), but none had histologic evidence of metastases. Serially euthanized liver xenografted mice revealed evidence of a gradual spontaneous metastatic model system with the first histologic findings of micrometastases appearing in the lungs by wk 5, which became wide spread by wk 7. Splenic and mediastinal lymph node metastases developed in wk 6 and 7. CONCLUSIONS: Liver xenografting of A549 cells into NOD/SCIDmice is a reliable way of developing widespread micrometastases. This model allows the study of a gradually developing solid tumor with subsequent metastatic spread.
Authors: C J Bruns; W Liu; D W Davis; R M Shaheen; D J McConkey; M R Wilson; C D Bucana; D J Hicklin; L M Ellis Journal: Cancer Date: 2000-08-01 Impact factor: 6.860
Authors: Ralph H Hruban; Anil K Rustgi; Teresa A Brentnall; Margaret A Tempero; Christopher V Wright; David A Tuveson Journal: Cancer Res Date: 2006-01-01 Impact factor: 12.701
Authors: David A Tuveson; Liqin Zhu; Aarthi Gopinathan; Nicholas A Willis; Leili Kachatrian; Rebecca Grochow; Christopher L Pin; Natalia Y Mitin; Elizabeth J Taparowsky; Phyllis A Gimotty; Ralph H Hruban; Tyler Jacks; Stephen F Konieczny Journal: Cancer Res Date: 2006-01-01 Impact factor: 12.701
Authors: Edward F Patz; Neil E Caporaso; Steven M Dubinett; Pierre P Massion; Fred R Hirsch; John D Minna; Constantine Gatsonis; Fenghai Duan; Amanda Adams; Charles Apgar; Rosa M Medina; Denise R Aberle Journal: J Thorac Oncol Date: 2010-10 Impact factor: 15.609
Authors: Andy J Minn; Yibin Kang; Inna Serganova; Gaorav P Gupta; Dilip D Giri; Mikhail Doubrovin; Vladimir Ponomarev; William L Gerald; Ronald Blasberg; Joan Massagué Journal: J Clin Invest Date: 2005-01 Impact factor: 14.808
Authors: Alexander Yu Nikitin; Ana Alcaraz; Miriam R Anver; Roderick T Bronson; Robert D Cardiff; Darlene Dixon; Armando E Fraire; Edward W Gabrielson; William T Gunning; Diana C Haines; Matthew H Kaufman; R Ilona Linnoila; Robert R Maronpot; Alan S Rabson; Robert L Reddick; Sabine Rehm; Nora Rozengurt; Hildegard M Schuller; Elena N Shmidt; William D Travis; Jerrold M Ward; Tyler Jacks Journal: Cancer Res Date: 2004-04-01 Impact factor: 12.701
Authors: D J Giard; S A Aaronson; G J Todaro; P Arnstein; J H Kersey; H Dosik; W P Parks Journal: J Natl Cancer Inst Date: 1973-11 Impact factor: 13.506
Authors: Dhruva K Mishra; Chad J Creighton; Yiqun Zhang; Fengju Chen; Michael J Thrall; Min P Kim Journal: Ann Thorac Surg Date: 2015-02-18 Impact factor: 4.330